Merck report this week that more than ninety percent of eligible U.S. claimants have elected to participate in its $4.85 billion proposed Vioxx settlement, and the drugmaker extended the deadline to opt in.
Merck said that, while it was satisfied with signing up the vast majority of potential participants, it was extending by two months -- until June 30 -- the deadline for remaining eligible former users of its withdrawn arthritis drug to enroll in its proposed settlement.
Link here.
